维克萨斯综合征的致命出血:一个致命的并发症揭露
Philippe Wöllenstein1, Florence Vallelian2, Zsuzsanna Varga3
1Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland philippe.woellenstein@usz.ch.
BMJ case reports
|July 16, 2025
概括
维克萨斯综合征是一种体质的UBA1突变疾病,导致严重的炎症和血液问题. 这种罕见疾病的早期诊断对于改善患者的治疗结果和预防血管炎等致命并发症至关重要.
科学领域:
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 维克萨斯综合征是一种成人发病的自身炎症性疾病.
- 它是由UBA1基因的体质突变引起的.
- 患有各种炎症和血液病症的患者.
研究的目的:
- 报告一个致命的VEXAS相关血管炎病例.
- 强调VEXAS综合征的临床谱和诊断挑战.
- 为了强调早期VEXAS诊断的重要性.
主要方法:
- 案例报告的呈现方式.
- 临床数据审查,包括患者病史和症状.
- 尸检后检查和基因检测UBA1突变.
主要成果:
- 在一个患有VEXAS综合征的患者身上发生了致命的逆皮质出血.
- 患者出现了复发性血栓炎,发烧,皮疹,关节炎和肺部透.
- 尸检结果证实了广泛的血管炎和UBA1突变的存在.
结论:
- 与VEXAS相关的血管炎可能是严重和危及生命的.
- 及时诊断和管理VEXAS综合征是必不可少的.
- 这一案例强调了早期识别的必要性,以改善患者的生存率.
相关概念视频
Esophageal Varices-I: Introduction
350
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
350
Esophageal Varices-II: Clinical Features and Management
146
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
146
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Venous Thrombosis I: Introduction
43
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
43
Vascular Spasm
1.9K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K


